DAVITA INC. - 10-Q Filing Summary
Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: DaVita operates principally as a dialysis and related lab services business, alongside ancillary services including infusion therapy, pharmacy, vascular access, and special needs plans. The company is a large accelerated filer with approximately 104.4 million shares of common stock outstanding as of July 31, 2008.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Three Months Ended June 30, 2007 |
Six Months Ended June 30, 2008 |
Six Months Ended June 30, 2007 |
|---|---|---|---|---|
| Net Operating Revenues | $1,407,304 | $1,312,735 | $2,752,028 | $2,590,901 |
| Operating Income | $205,554 | $261,217 | $402,281 | $454,534 |
| Net Income | $94,951 | $125,024 | $181,885 | $201,606 |
| Diluted EPS | $0.90 | $1.17 | $1.70 | $1.89 |
| Operating Cash Flow (6mo) | $225,534 (2008) vs $213,932 (2007) | |||
| Total Debt (Long-term + Current) | $3,709,313 (as of June 30, 2008) | |||
| Cash & Equivalents | $326,986 (as of June 30, 2008) |
Margins: Operating margin for the three months ended June 30, 2008, was approximately 14.6% ($205.6M / $1.407B). The filing does not explicitly state a consolidated net profit margin percentage, but net income was $94.95M for the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net operating revenues increased 7.2% year-over-year (YoY) for the quarter and 6.2% for the six-month period. This was driven by a 5.8% increase in the number of dialysis treatments and growth in ancillary services.
- Operating Income Decline: Operating income decreased 21.3% YoY for the quarter ($205.6M vs $261.2M). The prior year period included a non-recurring valuation gain of $55.3 million on an alliance and product supply agreement. Excluding this gain, operating income was flat compared to the prior year.
- Cost Pressures: Patient care costs increased due to higher labor costs, pharmaceutical costs, and medical supply costs. However, these were partially offset by a decrease in the intensity of physician-prescribed pharmaceuticals.
- Debt Expense: Debt expense decreased $7.6 million YoY for the quarter, primarily due to lower LIBOR-based variable interest rates on unhedged debt.
- Segment Performance: The "Dialysis and Related Lab Services" segment margin decreased from $292.9M to $237.7M YoY. The "Other - Ancillary Services" segment loss narrowed slightly from $10.7M to $9.6M.
Guidance, Outlook, and Risks
Guidance:
- 2008 Operating Income: Narrowed to a range of $800 million to $840 million.
- 2009 Operating Income: Projected range of $820 million to $880 million.
- Capital Expenditures (2008): Expected to spend $110M-$120M on routine maintenance/IT and $250M-$300M on new center development, relocations, and acquisitions.
- Operating Cash Flow (2008): Expected to generate $480M-$530M.
Management Commentary & Recent Developments:
- Medicare Legislation: The Medicare Improvements for Patients and Providers Act of 2008 was passed in July 2008. It introduces a new bundled payment system for dialysis services beginning in January 2011, with an initial rate set 2% below historical fee-for-service rates.
- Heparin Recall: A recall by Baxter Healthcare in February 2008 left only one supplier for heparin, significantly increasing costs. Fresenius Medical Care recently announced an agreement to acquire the sole provider, which could impact access and pricing.
- Share Repurchases: The company repurchased 3.46 million shares for $169.7 million in the first six months of 2008. An additional $143.5 million authorization was approved in May 2008, leaving $216.6 million available.
Risks and Contingencies:
- Government Investigations: The company is subject to ongoing civil and criminal investigations by the U.S. Attorney's Offices in Missouri, New York, and Texas, as well as the Office of Inspector General, regarding EPO utilization, billing practices, and relationships with physicians. Negative findings could result in substantial penalties or exclusion from Medicare/Medicaid.
- Commercial Payor Rates: Approximately 35% of revenue comes from commercial payors, which generate nearly all profits. Downward pressure on these rates poses a material risk.
- Regulatory Changes: Changes in Medicare ESRD payment structures and Medicaid eligibility could substantially reduce revenues.
Investor Verification Checklist
- Valuation Gain Impact: Verify the impact of the $55.3 million non-recurring gain in 2007 on year-over-year comparisons of operating income.
- Medicare Bundled Rate: Assess the potential financial impact of the 2011 bundled payment system, which is set 2% below historical rates, on future margins.
- Heparin Supply Chain: Monitor the acquisition of the sole heparin provider by a competitor (Fresenius affiliate) and its effect on input costs.
- Legal Exposure: Review the status of ongoing government investigations (Missouri, New York, Texas) regarding EPO billing and physician relationships for potential fines or exclusion risks.
- Commercial Mix: Track the percentage of patients covered by commercial insurance versus Medicare, as commercial payors drive the majority of profitability.